Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade

被引:1
作者
Vaneckova, Ivana [1 ]
Hojna, Silvie [1 ]
Vemerova, Zdenka [2 ]
Kadlecova, Michaela [1 ]
Rauchova, Hana [1 ]
Kompanowska-Jezierska, Elzbieta [3 ]
Vanourkova, Zdenka [4 ]
Cervenka, Ludek [4 ]
Zicha, Josef [1 ]
机构
[1] Czech Acad Sci, Inst Physiol, Dept Expt Hypertens, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic
[3] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Renai & Body Fluid Physiol, Warsaw, Poland
[4] Inst Clin & Expt Med, Prague, Czech Republic
关键词
hydrochlorothiazide; renoprotection; nephrectomy; atrasentan; chronic kidney disease; losartan; trandolapril; CHRONIC KIDNEY-DISEASE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR BLOCKADE; ENDOTHELIN ANTAGONISTS; HYPERTENSION; PROGRESSION; DRUGS; MODEL;
D O I
10.3389/fphys.2019.01145
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Objective: Our previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a model of chronic kidney disease (CKD) induced by partial nephrectomy. Since ETA blockade is known to cause edema, we were interested whether diuretic treatment added to this therapy would be beneficial. Design and Methods: Partial nephrectomy (NX) was performed at the age of 3 months in TGR rats which were subjected to: (i) RAS blockade alone (angiotensin receptor blocker losartan and angiotensin converting enzyme inhibitor trandolapril), (ii) combined RAS (losartan and trandolapril) and ETA receptor blockade (atrasentan), or (iii) diuretic (hydrochlorothiazide) added to the combined RAS + ETA blockade for 50 weeks following NX. Results: At the end of the study systolic blood pressure and cardiac hypertrophy were similarly decreased in all treated groups. Survival was significantly improved by ETA receptor blockade added to RAS blockade with no further effects of diuretic treatment. However, additional diuretic treatment combined with RAS + ETA blockade decreased body weight and had beneficial renoprotective effects - reductions of both kidney weight and kidney damage markers. Proteinuria gradually increased in rats treated with RAS blockade alone, while it was substantially lowered by additional ETA blockade. In rats treated with additional diuretic, proteinuria was progressively reduced throughout the experiment. Conclusion: A diuretic added to the combined RAS and ETA blockade has late renoprotective effects in CKD induced by partial nephrectomy in Ren-2 transgenic rats. The diuretic improved: renal function (evaluated as proteinuria and creatinine clearance), renal morphology (kidney mass, glomerular volume), and histological markers of kidney damage (glomerulosclerosis index, tubulointerstitial injury).
引用
收藏
页数:10
相关论文
共 45 条
[31]   The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease [J].
Raij, L .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (04) :95S-99S
[32]   Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats [J].
Rakusan, Dan ;
Kujal, Petr ;
Kramer, Herbert J. ;
Huskova, Zuzana ;
Vanourkova, Zdenka ;
Vernerova, Zdenka ;
Mrazova, Iveta ;
Thumova, Monika ;
Cervenka, Ludek ;
Vaneckova, Ivana .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2010, 299 (04) :F758-F766
[33]   THE ENHANCEMENT OF AMINONUCLEOSIDE NEPHROSIS BY THE COADMINISTRATION OF PROTAMINE [J].
SAITO, T ;
SUMITHRAN, E ;
GLASGOW, EF ;
ATKINS, RC .
KIDNEY INTERNATIONAL, 1987, 32 (05) :691-699
[34]   Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner [J].
Samad, Mohammed A. ;
Kim, Ui Kyoung ;
Kang, Joshua J. ;
Ke, Qingen ;
Kang, Peter M. .
PLOS ONE, 2015, 10 (03)
[35]   Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats [J].
Sedlakova, Lenka ;
Chabova, Vera Certikova ;
Dolezelova, Sarka ;
Skaroupkova, Petra ;
Kopkan, Libor ;
Huskova, Zuzana ;
Cervenkova, Lenka ;
Kikerlova, Sona ;
Vaneckova, Ivana ;
Sadowski, Janusz ;
Kompanowska-Jezierska, Elzbieta ;
Kujal, Petr ;
Kramer, Herbert J. ;
Cervenka, Ludek .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2017, 39 (02) :183-195
[36]   Thiazide Diuretics in Chronic Kidney Disease [J].
Sinha, Arjun D. ;
Agarwal, Rajiv .
CURRENT HYPERTENSION REPORTS, 2015, 17 (04)
[37]   Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - Overview and meta-analyses [J].
Thomopoulos, Costas ;
Parati, Gianfranco ;
Zanchetti, Alberto .
JOURNAL OF HYPERTENSION, 2015, 33 (02) :195-211
[38]   DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS [J].
Trachtman, Howard ;
Nelson, Peter ;
Adler, Sharon ;
Campbell, Kirk N. ;
Chaudhuri, Abanti ;
Derebail, Vimal Kumar ;
Gambaro, Giovanni ;
Gesualdo, Loreto ;
Gipson, Debbie S. ;
Hogan, Jonathan ;
Lieberman, Kenneth ;
Marder, Brad ;
Meyers, Kevin Edward ;
Mustafa, Esmat ;
Radhakrishnan, Jai ;
Srivastava, Tarak ;
Stepanians, Miganush ;
Tesar, Vladimir ;
Zhdanova, Olga ;
Komers, Radko .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (11) :2745-2754
[39]   Renoprotective Effects of ETA Receptor Antagonists Therapy in Experimental Non-Diabetic Chronic Kidney Disease: Is There Still Hope for the Future? [J].
Vaneckova, I. ;
Hojna, S. ;
Kadlecova, M. ;
Vernerova, Z. ;
Kopkan, L. ;
Cervenka, L. ;
Zicha, J. .
PHYSIOLOGICAL RESEARCH, 2018, 67 :S55-S67
[40]   Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade [J].
Vaneckova, Ivana ;
Rezacova, Lenka ;
Kunes, Jaroslav ;
Zicha, Josef .
LIFE SCIENCES, 2016, 159 :127-134